(PRWEB) February 19, 2013
The first Actos trial began today in Los Angeles court, according to Bloomberg.* Plaintiff Jack Cooper, 69, alleges that manufacturer Takeda Pharmaceutical failed to warn of the potential risk of bladder cancer and other side effects associated with the use of the drug. The Rottenstein Law Group, which represents clients in Actos bladder cancer lawsuits nationwide, will monitor the trial’s progress.
Jury selection was scheduled to begin today in the trial of In re: Cooper v. Takeda Pharmaceuticals America Inc. (CGC-12-518535, California Superior Court, Los Angeles). According to Bloomberg, Takeda faces more than 3,000 lawsuits across the United States, 1,200 of which were consolidated into a federal multidistrict litigation for pre-trial discovery expediency (MDL-2299). The first federal trial is set for November 2014. The remaining are in local jurisdictions.
Actos was at one point the world’s best-selling diabetes drug, but Takeda recently received approval for Nesina, a new diabetes drug to replace Actos, according to Bloomberg.
“The troubling thing about this is that Takeda has received approval for a new diabetes drug at a time when the company’s practices regarding Actos have been called into question in the courts,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “If the allegations of a cancer-link are true—and the company knew about it, as alleged in the lawsuit—then the company should be held accountable. Those who have taken Actos deserve to know the truth about the risks of the medication they were prescribed.”
The Rottenstein Law Group, a mass torts injury firm, encourages those who were prescribed Actos to download an informational brochure from its Actos Lawsuit Information Center to learn more about the drug and associated lawsuits and to help them evaluate if they have a case.
Actos entered the market in the United States in 1999, following approval by the FDA. According to Bloomberg, in 2012 a whistleblower alleged that Takeda ignored or downplayed concerns about the drug’s cancer risks before the drug when to market in 1999.
About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices. (Attorney advertising. Prior results do not guarantee a similar outcome.)
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com